Rosiglitazone reduces hepatic fat content

Rosiglitazone reduces hepatic fat content

Bibliographische Detailangaben
Hauptverfasser:	Buckingham, R, Toseland, C, Draper, N, Clarke, K
Format:	Journal article
Veröffentlicht:	2000

Ähnliche Einträge

Rosiglitazone prevents ischaemic injury in the obese Zucker rat heart
von: Sidell, R, et al.
Veröffentlicht: (2001)

Leukemia and rosiglitazone
von: Irfan Yavasoglu, et al.
Veröffentlicht: (2016-03-01)

Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
von: Soo Jin Yang, et al.
Veröffentlicht: (2014-01-01)

Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.
von: How, O, et al.
Veröffentlicht: (2007)

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
von: Kahn, SE, et al.
Veröffentlicht: (2006)

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
von: Lygate, C, et al.
Veröffentlicht: (2003)

Rosiglitazone-associated fractures in type 2 diabetes
von: Kahn, SE, et al.
Veröffentlicht: (2008)

Possible modulation of the antidiabetic effect of rosiglitazone by buspirone
von: Wafaa R. Mohamed, et al.
Veröffentlicht: (2012-06-01)

Incidence of diabetes following ramipril or rosiglitazone withdrawal
von: Holman, R, et al.
Veröffentlicht: (2011)

Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression
von: Lingling Yu, et al.
Veröffentlicht: (2023-04-01)

Guidance on rosiglitazone for type 2 diabetes mellitus.
von: Matthews, DR
Veröffentlicht: (2001)

Incidence of diabetes following ramipril or rosiglitazone withdrawal.
von: Investigators, D
Veröffentlicht: (2011)

Isolation, Synthesis and Characterization of Rosiglitazone Maleate Impurities
von: Singamsetty Radha Krishna, et al.
Veröffentlicht: (2008-01-01)

Budget impact of rosiglitazone in type 2 diabetes
von: Orietta Zaniolo, et al.
Veröffentlicht: (2007-03-01)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
von: Adie Viljoen, et al.
Veröffentlicht: (2009-04-01)

The autophagic regulation of rosiglitazone-promoted adipocyte browning
von: Yue Li, et al.
Veröffentlicht: (2024-06-01)

Hepatic Angiomyolipoma with Minimal Intratumoral Fat Content
von: Masataka Banshodani, et al.
Veröffentlicht: (2009-11-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
von: Mohammed A.Taher, et al.
Veröffentlicht: (2017-03-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
von: Mohammed A.Taher, et al.
Veröffentlicht: (2017-03-01)

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
von: Colin R Dormuth, et al.
Veröffentlicht: (2009-06-01)

RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
von: G. Rathinavel, et al.
Veröffentlicht: (2009-01-01)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression
von: Yong-lin Zhao, et al.
Veröffentlicht: (2016-01-01)

Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
von: Ensieh Salehi, et al.
Veröffentlicht: (2011-06-01)

Rosiglitazone as an option for patients with acromegaly: a case series
von: Bahena-García Ana, et al.
Veröffentlicht: (2011-05-01)

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
von: Schumacher Martin, et al.
Veröffentlicht: (2008-05-01)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
von: Demi C. Galindo, et al.
Veröffentlicht: (2020-07-01)

High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
von: Alejandro N. Rondón-Ortiz, et al.
Veröffentlicht: (2017-11-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin.
von: Colin R. Dormuth, et al.
Veröffentlicht: (2010-01-01)

Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞
von: Steven M. Watkins, et al.
Veröffentlicht: (2002-11-01)

Preventive effects of Salvia officinalis leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone
von: Mohamed R. Ben Khedher, et al.
Veröffentlicht: (2018-01-01)

Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
von: Rosauro Varo, et al.
Veröffentlicht: (2017-05-01)

Co-Administration of Conjugated Linoleic Acid and Rosiglitazone Increases Atherogenic Co-Efficient and Alters Isoprenaline-Induced Vasodilatation in Rats Fed High Fat Diet
von: Chai, Boon Kheng, et al.
Veröffentlicht: (2018)

Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
von: Soo Jin Yang, et al.
Veröffentlicht: (2011-01-01)

Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
von: Vladimir Kus, et al.
Veröffentlicht: (2011-01-01)

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?
von: Martine C. Morrison, et al.
Veröffentlicht: (2017-06-01)

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
von: Lachin, J, et al.
Veröffentlicht: (2011)

Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype
von: Hernan Sierra, et al.
Veröffentlicht: (2012-01-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
Veröffentlicht: (2010-01-01)

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
von: Zinman, B, et al.
Veröffentlicht: (2010)

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
von: Tan, G, et al.
Veröffentlicht: (2005)